There is likely some truth with the mention of Incyte’s adult GVHD drug by @Phaedrus in his latest reply to one of your previous posts, LeftYahoo, that there was a competitive consideration in how SI perhaps decided on using children’s aGVHD as a lead indication, given that the giant Novartis owns Incyte. So it might have been a miscalculation, and being too timid in deciding that as a small biotech, that was the best way forward ie. in avoiding head-on competition by going down the children’s indication. I do, however, agree that what it might have thought of as a strategic move has cost the company hugely.
@Led - what are your thoughts as to how to incorporate these considerations into the next steps?
- Forums
- ASX - By Stock
- MSB
- CEO Itescu needs to go
CEO Itescu needs to go, page-708
-
-
- There are more pages in this discussion • 200 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.00 |
Change
-0.010(0.99%) |
Mkt cap ! $1.158B |
Open | High | Low | Value | Volume |
$1.02 | $1.02 | $1.00 | $1.600M | 1.585M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 97944 | $1.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.01 | 78855 | 25 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
35 | 83648 | 1.005 |
18 | 184633 | 1.000 |
12 | 251610 | 0.995 |
9 | 542604 | 0.990 |
4 | 31677 | 0.985 |
Price($) | Vol. | No. |
---|---|---|
1.010 | 85623 | 26 |
1.015 | 96217 | 13 |
1.020 | 240432 | 20 |
1.025 | 104652 | 8 |
1.030 | 55189 | 2 |
Last trade - 14.55pm 19/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |